SOPHiA GENETICS and MD Anderson Partner for AI Revolution in Oncology

SOPHiA GENETICS and The University of Texas MD Anderson Cancer Center announced a strategic collaboration on January 7, 2026. The alliance aims to accelerate precision medicine using artificial intelligence. The partners will combine MD Anderson's clinical research expertise with the power of the SOPHiA DDM™ platform, which analyzes complex multimodal data (genomics, radiology, clinical data).

The collaboration will focus on developing new diagnostic tests and algorithms for selecting personalized therapies. AI will identify hidden patterns in tumor genetic codes, helping doctors find effective treatments even for rare forms of cancer. This partnership highlights the trend of converging big data and clinical practice: algorithms are becoming an integral part of the fight for patient lives.

Source: PR Newswire